Protalix BioTherapeutics (PLX) Issues Positive Update on PRX-102 Phase I/II; Improvements of Stabilization Noted
- Consumer staples stocks help Wall St. pare some losses
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
- Einhorn's Greenlight Mentions Caterpillar (CAT) Short in Q4 Letter; Doesn't See Disney (DIS) Buying Netflix (NFLX)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a recombinant, plant cell expressed, pegylated, modified version of the human alpha-Galactosidase-A enzyme.
“We are pleased to announce additional positive results from our phase I/II Fabry clinical trial,” said Moshe Manor, Protalix’s President and Chief Executive Officer. “The efficacy results seen to date continue to be very strong with improvements or stabilization in efficacy demonstrated across all disease parameters giving us confidence in our phase III head-to-head study comparing PRX-102 versus Fabrazyme®. The safety data is remarkable with all adverse events being mild to moderate and transient by nature and with antibodies decreasing or being eliminated for the very few patients who tested positive. We believe the product profile for PRX-102 has the potential to be highly differentiated from currently available enzyme replacement therapies for Fabry disease and could impact significantly the lives of patients suffering from this rare, genetic disease.”
The phase I/II clinical trial is an open-label, dose-ranging study designed to treat up to 18 naïve male and female adult patients. The three dose cohorts include 0.2 mg/kg, 1mg/kg and 2mg/kg with intravenous infusions of PRX-102 every two weeks.
The efficacy and safety analysis of the phase I/II clinical trial includes data from all 16 enrolled patients (9 male and 7 female) who completed the 12-month treatment period and, of more importance, a subset analysis of 10 patients who met the classic Fabry disease criteria (9 male and 1 female). The classic Fabry patient population is the most common Fabry patient population studied and reported on in the scientific and medical literature, and is the population to be evaluated in the Company’s phase III pivotal trial. Classic Fabry disease is characterized by having less than 30% residual enzyme activity, and typical manifestations involve neurological, skin, ophthalmic and Fabry-specific biomarkers.
Improvements or stabilization in efficacy were demonstrated across all disease parameters. Reductions of plasma Lyso-Gb3 ranged from 66.7 to 22.6 ng/ml in all patients and from 102.0 to 33.1 ng/ml in classic patients. Stable kidney function was also observed, as measured by estimated glomerular filtration rate (eGFR), with change from mean eGFR value of 110.78 at base line to 110.23 after 12 months for all patients, and from mean eGFR value of 117.37 to 117.36 for classic patients. All patients had stable cardiac function as measured by left ventricular mass (LVM) and left ventricular mass index (LVMI). The detailed results, as a percentage of change from base line, for both all patients and for the classic Fabry patient subset are presented in the following chart.
|% change ±SE||eGFR||LVM||LVMI||Gb3||lyso|
|All Patients (n=16)||-0.5 ±2.1||-0.0 ±2.5||0.4 ±2.6||-22.2 ± 6.1||-48.9 ± 5.7|
|Classic Patients (n=10)||-0.1±2.2||-2.6 ±3.4||-3.1 ±3.1||-33.3 ± 7.6||-57.6 ± 6.8|
The eGRF data in the foregoing table was measured using the Chronic Kidney Disease Epidemiology Collaboration analysis (CKD-EPI), which is the analysis the Company is using in its phase III pivotal trial of PRX-102, based on discussions with the U.S. Food and Drug Administration. The eGFR slope for all patients (n=16) using CKD-EPI was -2.9 (BL-77.7-156.3). The eGFR slope for classic Fabry patients (n=10) was -1.8 (BL 82.4-156.3). According to a published report, an annualized rate of eGFR change of -3.8 (BL 49-170) was observed in a study of the effect of Fabrazyme on the classic Fabry patient population using CKD-EPI analysis with similar base line of eGFR. The Company’s previously reported interim results for eGFR were analyzed using the MDRD equation, which is an older method and not commonly used in the clinical setting. Using MDRD, the eGFR slope is -3.25 for all patients (previously reported as -0.32), and -1.70 for classic patients.
PRX-102 also demonstrated, using the well-established BPI index, a substantial improvement in all pain parameters for all patients in the study, and an even more pronounced improvement in classic Fabry patients, as indicated below:
|Worse Pain||Average Pain||Pain Interference|
|Classic Fabry Patients||-38||%||-41||%||-44||%|
The safety analysis for adverse events represents a total of 26.2 patient years. PRX-102 was well tolerated, with the majority of adverse events being mild and moderate. Only one of the patients evaluated for safety experienced hypersensitivity. Only three patients developed antibodies and, after competing 12 months of treatment, one of those three patients has now tested negative for antibodies further supporting the potential of an immune tolerance phenomenon associated with the PRX-102 enzyme. Accordingly, the previously reported 19% incidence of treatment-induced anti-drug antibodies is now only 13%. Moreover, titers of the other two positive patients that developed antibodies have continued to decline over time.
Currently, all 16 patients enrolled in the trial continue to receive 1 mg/kg of PRX-102 in an open label extension trial. The Company is recruiting patients for the phase III pivotal trial in centers recently opened in the United States.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; PRX-110 for the treatment of Cystic Fibrosis; and others.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pulmatrix (PULM) Announces Drug Candidate Receives QIDP Designation from FDA
- EPAM Systems (EPAM), UBS Sign Strategic Multi-Year Agreement
- Facebook's virtual-reality tech was not stolen, Zuckerberg testifies
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!